FDA approves Baudax Bio’s ANJESO for pain

The FDA approved Baudax Bio’s (NASDAQ:BXRX) ANJESO for the management of moderate-to-severe pain, alone or in combination with other non-NSAID analgesics. ANJESO is a once-daily COX-2 preferential NSAID that is...

ReWalk Robotics

HCW cuts ReWalk Robotics PT to $3.50 from $9

H.C. Wainwright lowered its price target for ReWalk Robotics (NASDAQ:RWLK) to $3.50 from $9, reflecting dilution from a recent public offering. The stock closed at 81 cents on Feb. 20. As a result of the financing, the...


BTIG halves Endologix PT to $6 from $12

BTIG halved its price target for Endologix (NASDAQ:ELGX) to $6 from $12, but maintained its “buy” rating, saying the new target better reflects the current stock price, which closed at 89 cents on Feb. 19. Endologix...

Tivity Health

WB cuts Tivity Health to market perform

William Blair downgraded Tivity Health (NASDAQ:TVTY) to “market perform” after fourth quarter results missed consensus estimates and Tivity announced the departure of several senior executives. The stock closed at $22...


Sign up to our weekly BioTuesdays newsletter.